{"filing":{"accession_number":"0001213900-26-066821","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"ea0294064-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/ea0294064-8k_moonlake.htm"},"events":[{"id":5960,"run_id":5229,"accession_number":"0001213900-26-066821","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"MoonLake Immunotherapeutics held an Annual Meeting of shareholders at which four proposals were voted on and approved: election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, advisory vote on executive compensation, and approval of an amendment and restatement of the 2022 Equity Incentive Plan increasing available shares by 5,000,000 and extending the plan term to 2036.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5561,"accession_number":"0001213900-26-066821","item_number":"5.02","item_title":"Departure of Director or Certain Officers; Election of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment and restatement of the 2022 Equity Incentive Plan, which increases available shares for stock-based awards by 5,000,000 shares, incorporates a one-year minimum vesting requirement, revises non-employee director compensation limits, and extends the plan term to 2036. This is a material compensatory arrangement affecting equity grants and director compensation, fitting the exec_compensation category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:16.841649+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5562,"accession_number":"0001213900-26-066821","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing presents final vote tallies for four proposals: election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, advisory vote on executive compensation, and approval of an amendment and restatement of the 2022 Equity Incentive Plan. All proposals were approved, making this a material disclosure of shareholder actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:16.841649+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5561,"accession_number":"0001213900-26-066821","item_number":"5.02","item_title":"Departure of Director or Certain Officers; Election of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment and restatement of the 2022 Equity Incentive Plan, which increases available shares for stock-based awards by 5,000,000 shares, incorporates a one-year minimum vesting requirement, revises non-employee director compensation limits, and extends the plan term to 2036. This is a material compensatory arrangement affecting equity grants and director compensation, fitting the exec_compensation category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:16.841649+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-09"},{"id":5562,"accession_number":"0001213900-26-066821","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing presents final vote tallies for four proposals: election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, advisory vote on executive compensation, and approval of an amendment and restatement of the 2022 Equity Incentive Plan. All proposals were approved, making this a material disclosure of shareholder actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:16.841649+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-09"}]}